Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)Marie Robert, Jaafar Bennouna, Marta Jarlier et al.|Oncology|2017Cited by 55
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerPierre-Étienne Heudel, Jean-Luc Soubirou, Sylvie Chabaud et al.|ESMO Open|2021Cited by 35
Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer riskStéphanie Baert‐Desurmont, Agnès Hardouin, Rosine Guimbaud et al.|European Journal of Human Genetics|2015Cited by 17
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 CasesKinda Fattouh, Arnaud de la Fouchardière, Diane Collet-Benzaquen et al.|American Journal of Dermatopathology|2016Cited by 11
Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4).Marie Robert, Marta Jarlier, Thierry Conroy et al.|Journal of Clinical Oncology|2014Cited by 5